Latest operating income for MTCR: $-37M.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2022
Trailing 12 months ending Sep 30, 2022
Metacrine (MTCR) currently reports a operating income of $-37M as of September 2022. That compares with $-59M in the prior-year period — up 37.7% year over year. Use the charts on this page to explore Metacrine's operating income history and peer comparisons.
Metacrine's operating income increased from $-59M to $-37M — a 37.7% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Metacrine reported $-37M in operating income as of September 2022. That compares with $-59M in the prior-year period — up 37.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current operating income of $-37M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Metacrine, and consider following MTCR for alerts when major investors trade the stock.
Metacrine is classified in the Healthcare sector. On operating income, it currently shows $-37M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MTCR with unrelated industries.